Slate Medicines has emerged with hopes of cracking the code for delivering an injectable novel drug class to prevent ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...

Allurion saw its shares jump roughly 60% on Monday, Feb. 23, as the FDA signed off on the medtech’s premarket approval ...

GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from China’s Frontier Biotechnologies. | GSK is continuing to bolster its siRNA ...

Novo Nordisk and its Chinese partner have reported up to 19.7% weight loss in patients who took their triple agonist for 24 weeks, illuminating a potential path forward for the Danish drugmaker as it ...

With its cash cache set to run out by the fourth quarter of this year, Werewolf Therapeutics is prowling the biotech landscape for a deal to keep its pipeline afloat. | With its cash cache set to run ...

Galapagos took a 228 million euro ($269 million) hit last year as it began to close its cell therapy business, but the Belgian biopharma is confident it can stabilize its finances by the end of the ...

Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by deploying Evinova’s AI-native platform in an effort to speed up clinical development.

Under an agreement announced Monday, Feb. 23, Organon will pay $27.5 million upfront for the right to market Sebela’s Miudella, billed as the first FDA-approved device of its kind in 40 years.

Harbour BioMed is setting sail as the Solstice begins, riding the waves of biobucks potential that could reach heights up to $1.1 billion. | Harbour BioMed is setting sail as the Solstice begins, ...

A year after Abcuro raised $200 million to fund a phase 2/3 muscle disease trial of its anti-KLRG1 antibody, the study has ...

The FDA has ordered MacroGenics to halt enrollment in a phase 2 trial of the biotech’s lead candidate lorigerlimab following severe side effects that led to one patient death.